Macrogenics
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 339
- Market Cap
- $215.1M
- Introduction
MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E...
Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 95
- Registration Number
- NCT02689284
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
🇸🇬Raffles Hospital, Singapore, Singapore
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of
Safety Study of MGD009 in B7-H3-expressing Tumors
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 67
- Registration Number
- NCT02628535
- Locations
- 🇺🇸
Stanford University School of Medicine, Palo Alto, California, United States
🇺🇸Columbia University Medical Center, New York, New York, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 624
- Registration Number
- NCT02492711
- Locations
- 🇺🇸
East Valley Hematology And Oncology, Burbank, California, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Tennessee Oncology, PLLC, Chattanooga, Tennessee, United States
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2021-09-28
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 145
- Registration Number
- NCT02475213
- Locations
- 🇺🇸
Mayo Clinic - AZ, Scottsdale, Arizona, United States
🇺🇸Norton Cancer Institute Research Program, Louisville, Kentucky, United States
🇺🇸South Texas Accelerated Research Therapeutics, LLC - Midwest, Grand Rapids, Michigan, United States
Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 24
- Registration Number
- NCT02381314
- Locations
- 🇺🇸
Center for Oncology and Blood Disorders, Houston, Texas, United States
🇺🇸Yale University, New Haven, Connecticut, United States
🇺🇸Mount Sinai Medical Center, Miami Beach, Florida, United States
Phase 1 Study of MGD010 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-03-03
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 73
- Registration Number
- NCT02376036
- Locations
- 🇺🇸
PAREXEL Baltimore Early Phase Clinical Unit, Baltimore, Maryland, United States
Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 95
- Registration Number
- NCT02248805
- Locations
- 🇺🇸
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸H. Lee Moffitt Cancer Center & Research Institute, Inc, Tampa, Florida, United States
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
- Conditions
- Interventions
- Biological: Flotetuzumab 3 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 10 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 30 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 100 ng/kg/day, 4 days on and 3 days offBiological: Flotetuzumab 300 ng/kg/day, 4 days on 3 days off, after one-step lead-in doseBiological: Flotetuzumab 500 ng/kg/day, 4 days on 3 days off, after one-step lead-in doseBiological: Flotetuzumab 500 ng/kg/day, continuous infusion, after multi-step lead-in doseBiological: Flotetuzumab 700 ng/kg/day, 4 days on 3 days off, after multi-step lead-in doseBiological: Flotetuzumab 300 ng/kg/day, continuous infusion, after multi-step lead-in doseBiological: Flotetuzumab 700 ng/kg/day, continuous infusion, after multi-step lead-in doseDrug: Ruxolitinib
- First Posted Date
- 2014-06-02
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 244
- Registration Number
- NCT02152956
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
Tissue Procurement Substudy for Participants in Study CP-MGA271-01
- First Posted Date
- 2013-08-08
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 6
- Registration Number
- NCT01918930
- Locations
- 🇺🇸
UCLA Hematology-Oncology Clinic, Los Angeles, California, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- MacroGenics
- Target Recruit Count
- 25
- Registration Number
- NCT01828021
- Locations
- 🇺🇸
Tufts Cancer Center, Boston, Massachusetts, United States
🇺🇸Florida Cancer Research Institute, Plantation, Florida, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States